---
title: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy
date: '2024-05-13'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38739079/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20240513180733&v=2.18.0.post9+e462414
source: N Engl J Med
description: 'CONCLUSIONS: Among patients with symptomatic obstructive HCM, treatment
  with aficamten resulted in a significantly greater improvement in peak oxygen uptake
  than placebo. (Funded by Cytokinetics; SEQUOIA-HCM ClinicalTrials.gov number, ...'
disable_comments: true
---
CONCLUSIONS: Among patients with symptomatic obstructive HCM, treatment with aficamten resulted in a significantly greater improvement in peak oxygen uptake than placebo. (Funded by Cytokinetics; SEQUOIA-HCM ClinicalTrials.gov number, ...